显示标签为“kidney”的博文。显示所有博文
显示标签为“kidney”的博文。显示所有博文

2016年4月27日星期三

Pain can accelerate the speed of kidney failure and increase the risk of death

A study published recently in the Journal AJKD explored the relevance of pain with renal dysfunction and the development and risk of death of chronic kidney diseases. The results showed that moderate-severe pain can accelerate the rate of decline in kidney function, increasing risk of death.

The retrospective cohort study included 2,360,056 American veterans, nearly 60% of which had pain problems and common paregoric for them are opioid analgesics. The estimated baseline of glomerular filtration rate (eGFR) is ≥ 60 mL / min / 1.73 m2. Pain rating: None (0), mild (1-4 points) and severe (5-6), and severe (≥ 7 points). Endpoint: eGFR declines and incidence of eGFR <60 mL / min / 1.73 m2 or all-cause mortality.

After adjustment for baseline eGFR level, demographics, comorbidities, cardiovascular risk factors and depression, use Cox proportional hazards regression model with pain (1) eGFR decreased rapidly; (2) eGFR <60 mL / min / 1.73 m2 occurred or all-cause mortality rate correlation.

It was found that the risk of eGFR rapidly decline in patients with moderate and severe pain was much higher than that of those without pain or with mild pain. The ratio of patients with moderate pain was 1.11 (95% confidence interval 1.09-1.14); the radio of patients with severe pain was 1.17 (95% confidence interval 1.13-1.21). Patients with moderate and severe pain had the risk of eGFR <60 mL / min / 1.73 m2 or risk of death 30% higher than those without pain. The risk radio of patients with moderate pain was 1.30 (95% confidence interval 1.28-1.31), the risk ratio of patients with severe pain was 1.30 (95% confidence interval 1.28-1.32).

Although this study has several limitations (a lack of detailed data on the types of pain and pain location), it still shows that pain is associated with the increase of incidence rate of eGFR <60 mL / min / 1.73 m2, the speed of decline in renal function and mortality.

More details: http://www.cusabio.com/Recombinant-Protein/Recombinant-Escherichia-coli-O6:H1-strain-CFT073--ATCC-700928--UPEC-Inner-membrane-transport-permease-YbhS-11106397.html

2016年2月19日星期五

Great breakthrough in implantable artificial kidney which is based on chip

The kidney is an amazing organ. It continues to work for 24 hours a day cleaning the blood and dealing with waste disposal. Every day, these organs which are on both sides of the spine and below the ribs, with a shape of soy and fist-size, filter 150 liters of blood and produce 12 liters of urine.

Transplantation is the best treatment of renal failure, but the demand for organs far greater than the supply. US Organ Procurement and Transplantation Network said there are more than 100,000 patients waiting for kidney transplant list, but last year, only 17,108 patients to get transplants.

Overall, the National Kidney Foundation estimates that more than 460,000 Americans suffer from end-stage renal disease, and 13 patients have died while waiting for kidney donation during the day in the United States. They say love kidney disease Medicare bill - including prescription drugs, including - - 2012 is about $ 87 billion.

Kidney specialist and assistant professor of medicine at the University of Tennessee Medical Center Nashville van Magdeburg, nephrologist William H. Fissell IV and his research team hopes to end this disastrous scenario, he said, "We are developing a biological mixing device can be simulated kidneys remove enough waste, salt and water, so that the patient no longer needs dialysis "goal is to produce a device small enough - approximately the size of the bottle size - so you can put patient. Implantable artificial kidney filters and contains a microchip living kidney cells and energy supply by the patient's own heart.

The kidneys project was started over a decade ago. In 2003, it received the first batch of financial allocations from the National Institutes of Health (NIH), the recent US National Institutes of Health (NIH) to Fissell professor and his research partner, the University of California, San Francisco longtime collaborator Shuvo Roy providing up to 4 years, up to $ 6 million in funding.

In 2012, the Food and Drug Administration (FDA) to give fast-track review of the project - one is used to promote and accelerate for the treatment of serious illness and possibly resolve not meet the medical needs of the current review of the way the drug. The team hopes to be able to carry out before the end of 2017 pilot studies of silicon filter. Professor Fissell said he had a lot of patients eager to participate, he expressed admiration for these patients. As he concluded, "My patient is definitely my hero. Again and again they came back from the jaws of death. They accepted the heavy burden of disease, because they want to survive. They are willing to bear all the risk to other patients."

Refer to this link: http://www.cusabio.com/Polyclonal-Antibody/Rabbit-anti-human-DNA-replication-licensing-factor-MCM3-polyclonal-AntibodyMCM3-11106199.html